AgomAb Therapeutics (NASDAQ:AGMB) Stock Dropped to Sell by Wall Street Zen

Wall Street Zen lowered shares of AgomAb Therapeutics (NASDAQ:AGMB) from a hold rating to a sell rating in a report issued on Sunday morning,Wall Street Zen reports.

Other equities analysts have also recently issued reports about the stock. Piper Sandler began coverage on shares of AgomAb Therapeutics in a research note on Tuesday, August 25th. They set an “overweight” rating and a $60.00 price target for the company. HC Wainwright reissued a “buy” rating on shares of AgomAb Therapeutics in a research report on Wednesday, September 16th. Cantor Fitzgerald assumed coverage on shares of AgomAb Therapeutics in a report on Wednesday, August 19th. They set an “overweight” rating for the company. Finally, B. Riley Financial assumed coverage on shares of AgomAb Therapeutics in a research report on Thursday, July 23rd. They issued a “buy” rating and a $34.00 target price for the company. Seven research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $37.50.

AgomAb Therapeutics Price Performance

AGMB stock opened at $10.51 on Friday. AgomAb Therapeutics has a fifty-two week low of $8.75 and a fifty-two week high of $17.82. The business has a 50-day moving average of $13.20 and a 200-day moving average of $12.21.

AgomAb Therapeutics (NASDAQ:AGMB) last announced its earnings results on Thursday, August 6th. The company reported ($0.46) earnings per share (EPS) for the quarter. On average, equities analysts predict that AgomAb Therapeutics will post -1.76 EPS for the current fiscal year.

AgomAb Therapeutics Company Profile

AgomAb Therapeutics N.V. (NASDAQ: AGMB) is a clinical-stage biopharmaceutical company developing medicines for diseases involving tissue damage, fibrosis and impaired regeneration. The company’s approach includes modulating biological pathways that influence tissue repair and remodeling, with the goal of addressing conditions with significant unmet medical needs.

AgomAb’s lead clinical program is AGMB-129, an oral, gut-restricted inhibitor of activin receptor-like kinase 5 (ALK5), a receptor involved in transforming growth factor beta signaling.